Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 25:14:1198602.
doi: 10.3389/fendo.2023.1198602. eCollection 2023.

Inflammation mediates the effect of adiposity and lipid metabolism indicators on the embryogenesis of PCOS women undergoing in vitro fertilization/intracytoplasmic sperm injection

Affiliations

Inflammation mediates the effect of adiposity and lipid metabolism indicators on the embryogenesis of PCOS women undergoing in vitro fertilization/intracytoplasmic sperm injection

Huahua Jiang et al. Front Endocrinol (Lausanne). .

Abstract

Background: Polycystic ovary syndrome (PCOS) is a complex reproductive endocrine and metabolic disease affecting women of reproductive age. The low-grade chronic inflammation in PCOS is considered to be associated with obesity and dyslipidemia. We aim to investigate the potential mediating role of white blood cell (WBC) count, a representative inflammatory marker, in the effect of adiposity and lipid metabolism indicators on IVF/ICSI outcomes in PCOS women.

Methods: We conducted a retrospective cohort study of 1,534 PCOS women who underwent their first IVF/ICSI cycles with autologous oocytes at a reproductive center from January 2018 to December 2020. The associations between PCOS women's adiposity and lipid metabolism indicators and WBC count and IVF/ICSI outcomes were examined using multivariable generalized linear models. Mediation analyses were conducted to evaluate the possible mediating role of WBC count.

Results: We found significant dose-dependent correlations between adiposity and lipid metabolism indicators and IVF/ICSI outcomes (i.e., hormone levels on the ovulatory triggering day, oocyte development outcomes, fertilization, early embryo development outcomes, and pregnancy outcomes) (all p < 0.05), as well as between adiposity and lipid metabolism indicators and WBC count (all p < 0.001). Increasing WBC count was associated with adverse oocyte and embryonic development outcomes (all p < 0.05). Mediation analyses suggested that increasing serum TG and LDL-C levels and decreasing serum HDL-C level were significantly associated with reduced high-quality Day 3 embryo count in PCOS women, with 21.51%, 9.75%, and 14.10% mediated by WBC count, respectively (all p < 0.05).

Conclusions: We observed significant associations between lipid metabolism indicators and high-quality Day 3 embryo count in PCOS women, partially mediated by inflammation-related mechanisms, suggesting the potential intervention target for improving embryo quality in PCOS women.

Keywords: IVF/ICSI outcomes; PCOS; adiposity; inflammation; lipid metabolism; mediating effect.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Mediating effects of WBC count on the associations between adiposity and lipid metabolism indicators and high-quality Day 3 embryo count. Adjusted for age (continuous), AFC (continuous), and infertility type. Adiposity and lipid metabolism indicators and WBC count were transformed by natural logarithm. ACME: average causal mediating effect. This represents the indirect effect, also known as the mediating effect of WBC count on the associations between adiposity and lipid metabolism indicators and high-quality embryo count. ADE: average direct effect. This represents the effects of adiposity and lipid metabolism indicators on high-quality Day 3 embryo count when WBC count is controlled. *p < 0.05. **p < 0.01.

References

    1. Joham AE, Norman RJ, Stener-Victorin E, Legro RS, Franks S, Moran LJ, et al. . Polycystic ovary syndrome. Lancet Diabetes Endocrinol (2022) 10(9):668–80. doi: 10.1016/S2213-8587(22)00163-2 - DOI - PubMed
    1. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod (2004) 19(1):41–7. doi: 10.1093/humrep/deh098 - DOI - PubMed
    1. Xu Y, Zhu H, Li W, Chen D, Xu Y, Xu A, et al. . Targeting adipokines in polycystic ovary syndrome and related metabolic disorders: from experimental insights to clinical studies. Pharmacol Ther (2022) 240:108284. doi: 10.1016/j.pharmthera.2022.108284 - DOI - PubMed
    1. Zhu T, Goodarzi MO. Causes and consequences of polycystic ovary syndrome: insights from mendelian randomization. J Clin Endocrinol Metab (2022) 107(3):e899–911. doi: 10.1210/clinem/dgab757 - DOI - PMC - PubMed
    1. Chudzicka-Strugała I, Gołębiewska I, Banaszewska B, Brudecki G, Zwoździak B. The role of individually selected diets in obese women with PCOS-a review. Nutrients (2022) 14(21):4555. doi: 10.3390/nu14214555 - DOI - PMC - PubMed

Publication types